ReviewCancer metastasis reviews2025
Macrophage regulation of tumor cell dormancy and the dormant niche: an overview in solid tumors.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- Regulating the dormancy of cancer stem cells: a novel approach to preventing cancer relapse.Cell death & disease · 2026Review
- Orchestrating the pre-metastatic niche: roles of stromal mediators and immune cells in metastatic progression and therapeutic targeting.Frontiers in immunology · 2026Review
- Breast Cancer Recurrence After 46 Years of Remission: A Case Report and Clinical Implications.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tumor recurrence often occurs years after initial treatment, driven by dormant tumor cells that evade detection and therapy. These quiescent cells can persist in primary or metastatic niches and later reawaken under favorable microenvironmental conditions, contributing to cancer relapse. Tumor-associated macrophages (TAMs) have emerged as key regulators in orchestrating this proliferation-dormancy switch. Through secretion of cytokines, extracellular vesicles, and direct cellular interactions, macrophages influence tumor cell fate via multiple signaling pathways, including TGF-β, WNT, and HIPPO. These pathways modulate the expression of cell cycle regulators, such as cyclins and cyclin-dependent kinase inhibitors (CKIs), ultimately governing the transition between proliferation and dormancy. This review synthesizes current findings on the roles of macrophages in initiating and maintaining tumor cell dormancy across various solid tumors. We discuss how distinct macrophage subtypes-defined by developmental origin or polarization state-differentially engage with tumor cells to modulate dormancy-associated signaling cascades. Understanding these spatiotemporal interactions between macrophages and tumor cells offers novel opportunities for therapeutic intervention aimed at preventing relapse by targeting the dormant tumor cell niche.
Indexed as
Identifiers
40762813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.